# The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

Source: https://onco.cc/trials/nct02653755/  
OnCo record `nct02653755` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Prosigna in Breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.

## Summary

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer is a phase 2 interventional study registered as NCT02653755 by Dana-Farber Cancer Institute, with 671 participants planned, started 2015-12-15 and due to reach its primary completion in 2030-05-15. Interventions recorded: Prosigna. Conditions recorded: Breast Cancer Radiation.

Linked to the drug Prosigna because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02653755
- Phase: 2
- Setting: The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 671

## Sources

- ClinicalTrials.gov NCT02653755: https://clinicaltrials.gov/study/NCT02653755

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Prosigna (PAM50)](https://onco.cc/drugs/prosigna/)

---
JSON: https://onco.cc/api/v1/entities/nct02653755.json